This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| Wuhan | 4957 |
| COVID-19 | 3937 |
| SARS | 3867 |
| China | 3813 |
| CoV-2 | 2278 |
| el | 1548 |
| January | 1154 |
| Hubei | 966 |
| los | 892 |
| Coronavirus | 789 |
| CoV | 766 |
| PCR | 713 |
| Health | 686 |
| February | 681 |
| con | 679 |
| para | 606 |
| Table | 551 |
| Fig | 544 |
| del | 539 |
| MERS | 523 |
| un | 507 |
| CT | 425 |
| pacientes | 415 |
| las | 411 |
| March | 395 |
| una | 394 |
| Province | 382 |
| en | 369 |
| Disease | 368 |
| Novel | 357 |
| ACE2 | 348 |
| mcr-9 | 324 |
| December | 315 |
| Hospital | 314 |
| RNA | 285 |
| Se | 282 |
| por | 279 |
| como | 278 |
| National | 245 |
| CC | 241 |
| K. | 239 |
| C | 238 |
| CI | 225 |
| medRxiv | 224 |
| World | 217 |
| EHV | 216 |
| es | 214 |
| RT | 214 |
| Chinese | 212 |
| UK | 211 |
| BY | 208 |
| ICU | 205 |
| Shanghai | 203 |
| uso | 202 |
| Organization | 200 |
| United | 199 |
| East | 199 |
| PJP | 198 |
| LF | 198 |
| Commission | 197 |
| Beijing | 197 |
| Clinical | 196 |
| ND | 196 |
| NC | 196 |
| PJ | 190 |
| La | 190 |
| recomienda | 189 |
| Middle | 185 |
| ARDS | 185 |
| mg | 182 |
| New | 172 |
| HCV | 172 |
| Europe | 172 |
| States | 171 |
| CR | 171 |
| Wang | 171 |
| B. | 169 |
| Control | 166 |
| Pneumonia | 165 |
| City | 163 |
| T | 162 |
| PRV | 162 |
| Italy | 161 |
| University | 160 |
| Jan | 157 |
| US | 156 |
| su | 155 |
| S | 154 |
| • | 154 |
| sha | 151 |
| Li | 151 |
| ventilación | 147 |
| B | 144 |
| puede | 143 |
| S1 | 143 |
| Feb | 143 |
| April | 142 |
| L | 138 |
| Huanan | 137 |
| Guangdong | 136 |
| 136 | |
| People | 135 |
| colistin | 135 |
| Shenzhen | 135 |
| Figure | 134 |
| Prevention | 134 |
| Chen | 130 |
| Zhang | 127 |
| ser | 126 |
| paciente | 126 |
| Public | 126 |
| Leishmania | 126 |
| DOI | 126 |
| Japan | 124 |
| WHO | 123 |
| Zhejiang | 123 |
| Korea | 122 |
| Spain | 121 |
| Republic | 119 |
| CDC | 119 |
| A | 119 |
| Science | 118 |
| J | 118 |
| USA | 117 |
| CRKP | 117 |
| meta | 116 |
| AMCI | 115 |
| PPE | 114 |
| diagnóstico | 113 |
| M | 113 |
| enfermedad | 112 |
| Respiratory | 112 |
| tratamiento | 111 |
| UCI | 111 |
| IgM | 111 |
| lo | 110 |
| riesgo | 109 |
| estudios | 109 |
| IgG | 108 |
| Syndrome | 108 |
| Transmission | 107 |
| mortalidad | 106 |
| estudio | 105 |
| debe | 105 |
| Medical | 105 |
| Spring | 104 |
| El | 104 |
| más | 103 |
| Klebsiella | 103 |
| IQR | 102 |
| SEIR | 102 |
| CoVs | 101 |
| Pneumocystis | 100 |
| Market | 100 |
| Liu | 100 |
| International | 100 |
| Hong | 100 |
| Lassa | 99 |
| Center | 99 |
| Baidu | 99 |
| South | 98 |
| Festival | 98 |
| E. | 98 |
| manejo | 97 |
| se | 96 |
| Huang | 96 |
| Henan | 95 |
| días | 93 |
| LDH | 93 |
| Wu | 92 |
| Guangzhou | 92 |
| Analysis | 92 |
| Kong | 90 |
| Medicine | 89 |
| Care | 89 |
| Journal | 88 |
| SDRA | 87 |
| D | 87 |
| mecánica | 86 |
| Supplementary | 86 |
| S2 | 86 |
| Seafood | 85 |
| Ebola | 85 |
| sospecha | 83 |
| Society | 82 |
| Cov-2 | 82 |
| IL-6 | 81 |
| Germany | 81 |
| HIV | 81 |
| Hunan | 81 |
| entre | 81 |
| Patients | 81 |
| SPD | 81 |
| mcr | 81 |
| Treatment | 80 |
| R | 80 |
| PM | 80 |
| England | 80 |
| Fang | 78 |
| Committee | 78 |
| Group | 78 |
| casos | 78 |
| han | 77 |
| Data | 77 |
| Los | 77 |
| Year | 76 |
| AI | 76 |
| sobre | 75 |
| May | 75 |
| Association | 75 |
| L. | 74 |
| Emergency | 74 |
| mayor | 74 |
| pulmonar | 73 |
| intubación | 73 |
| Nigeria | 73 |
| Infection | 73 |
| CFR | 73 |
| preprint | 73 |
| jirovecii | 72 |
| alta | 72 |
| London | 72 |
| pueden | 71 |
| HCWs | 71 |
| esta | 71 |
| ritonavir | 71 |
| cuidados | 70 |
| E | 70 |
| respiratoria | 69 |
| grupo | 69 |
| Yang | 69 |
| Institute | 69 |
| Daegu | 69 |
| remdesivir | 68 |
| Remdesivir | 68 |
| Lancet | 67 |
| Report | 67 |
| lymphopenia | 67 |
| fue | 66 |
| N | 66 |
| Boltzmann | 66 |
| presión | 65 |
| personal | 65 |
| Research | 65 |
| RBD | 65 |
| Epidemiology | 65 |
| Asia | 65 |
| Covid-19 | 64 |
| Team | 64 |
| R0 | 64 |
| U | 64 |
| día | 64 |
| nan | 63 |
| Lombardy | 63 |
| June | 63 |
| Jiang | 63 |
| Enterobacterales | 63 |
| DAA | 63 |
| CFU | 63 |
| October | 62 |
| RAS | 62 |
| evidencia | 61 |
| Singapore | 61 |
| Model | 61 |
| Foundation | 61 |
| Characteristics | 61 |
| BAL | 61 |
| Study | 60 |
| HCQ | 60 |
| Molecular | 60 |
| PM2.5 | 60 |
| II | 60 |
| Virus | 60 |
| este | 60 |
| infección | 60 |
| lopinavir | 60 |
| tiempo | 60 |
| Tokyo | 59 |
| September | 59 |
| F | 59 |
| Pandemic | 58 |
| Infectious | 58 |
| CRP | 58 |
| America | 58 |
| PR | 57 |
| clínico | 57 |
| kg | 57 |
| salud | 57 |
| ≤ | 55 |
| horas | 55 |
| clínica | 55 |
| York | 55 |
| TA | 55 |
| HC | 55 |
| CMV | 55 |
| soporte | 54 |
| menor | 54 |
| Nowcasting | 54 |
| NIPH | 54 |
| H1N1 | 54 |
| Human | 53 |
| RaTG13 | 53 |
| IC | 52 |
| First | 52 |
| Early | 52 |
| síntomas | 51 |
| cols | 51 |
| bajo | 51 |
| N95 | 51 |
| Mainland | 51 |
| alto | 50 |
| Appendix | 50 |
| College | 50 |
| Las | 50 |
| SPSS | 50 |
| cuenta | 50 |
| fueron | 50 |
| protección | 50 |
| si | 50 |
| pero | 49 |
| State | 49 |
| Yu | 48 |
| Technology | 48 |
| Review | 48 |
| ECMO | 48 |
| Case | 48 |
| TMPRSS2 | 47 |
| Global | 47 |
| Management | 47 |
| atención | 47 |
| realizar | 47 |
| dosis | 47 |
| Diseases | 46 |
| Emergence | 46 |
| Influenza | 46 |
| Municipal | 46 |
| NHS | 46 |
| Qiagen | 46 |
| TNF | 46 |
| Viral | 46 |
| ZJ01 | 46 |
| Zhou | 46 |
| contra | 46 |
| deben | 46 |
| hasta | 46 |
| inicio | 46 |
| nivel | 46 |
| respiratorio | 46 |
| son | 46 |
| Epidemic | 45 |
| MDR | 45 |
| clínicos | 45 |
| EHV4 | 45 |
| Development | 45 |
| Response | 45 |
| Outbreak | 45 |
| compromiso | 45 |
| SMX | 45 |
| VL | 45 |
| oxigenación | 45 |
| ±10 | 45 |
| Toronto | 45 |
| Thailand | 44 |
| AKI | 44 |
| Med | 44 |
| Taiwan | 44 |
| aguda | 44 |
| intensivos | 44 |
| oxígeno | 44 |
| pandemia | 44 |
| − | 44 |
| SIR | 43 |
| Centre | 43 |
| Paris | 43 |
| Q | 43 |
| Chongqing | 43 |
| Union | 43 |
| mejoría | 43 |
| niveles | 43 |
| severa | 43 |
| críticos | 43 |
| Xu | 42 |
| Africa | 42 |
| Detection | 42 |
| En | 42 |
| Risk | 42 |
| July | 42 |
| cual | 42 |
| número | 42 |
| otros | 42 |
| vía | 42 |
| −1 | 42 |
| ® | 41 |
| todos | 41 |
| terapia | 41 |
| der | 41 |
| SAS | 41 |
| Jiangsu | 41 |
| Impact | 41 |
| France | 41 |
| Central | 41 |
| Hu-1 | 40 |
| DM | 40 |
| PH | 40 |
| resultados | 40 |
| Tang | 40 |
| seguridad | 39 |
| pronóstico | 39 |
| ingreso | 39 |
| ST | 39 |
| Investigation | 39 |
| DNA | 39 |
| COVID | 39 |
| PIBA | 38 |
| Natural | 38 |
| IV | 38 |
| J. | 38 |
| KRSFIEDLLFNKV | 38 |
| recursos | 38 |
| china | 38 |
| dos | 38 |
| severo | 38 |
| Panel | 37 |
| Jan. | 37 |
| Joint | 37 |
| estrategia | 37 |
| IFN | 37 |
| Dr. | 37 |
| Wei | 37 |
| S3 | 37 |
| utilizar | 37 |
| Wholesale | 37 |
| convaleciente | 37 |
| decisiones | 37 |
| doi | 37 |
| falla | 37 |
| recibieron | 37 |
| Montenegro | 36 |
| EPP | 36 |
| HSV | 36 |
| G.F.G. | 36 |
| HCU | 36 |
| EHV1 | 36 |
| Diagnosis | 36 |
| AST | 36 |
| TMP | 36 |
| OXA-48 | 36 |
| NDM-1 | 36 |
| Trust | 36 |
| covid-19 | 36 |
| realización | 36 |
| donde | 36 |
| d3 | 36 |
| durante | 36 |
| baja | 36 |
| tipo | 36 |
| Zhu | 36 |
| VIM-1 | 36 |
| Lunar | 35 |
| ACE-2 | 35 |
| Candida | 35 |
| Changsha | 35 |
| Dynamics | 35 |
| Hebei | 35 |
| Hydroxychloroquine | 35 |
| I | 35 |
| European | 35 |
| RR | 35 |
| flujo | 35 |
| Rapid | 35 |
| manera | 35 |
| hipoxemia | 35 |
| sido | 35 |
| sugiere | 35 |
| crítico | 35 |
| System | 35 |
| Y | 34 |
| C. | 34 |
| CD4 | 34 |
| ELISA | 34 |
| HCoV | 34 |
| Ministry | 34 |
| Sciences | 34 |
| 34 | |
| desde | 34 |
| Zhao | 34 |
| cuales | 34 |
| equipo | 34 |
| medidas | 34 |
| menos | 34 |
| posición | 34 |
| sera | 34 |
| Estimation | 33 |
| Por | 33 |
| Intensive | 33 |
| Treat | 33 |
| Cox | 33 |
| COV-2 | 33 |
| Social | 33 |
| ROC | 33 |
| doc_id | 33 |
| tiene | 33 |
| vida | 33 |
| estos | 33 |
| considerar | 33 |
| diferentes | 33 |
| control | 33 |
| R. | 32 |
| (= | 32 |
| Anhui | 32 |
| Arabia | 32 |
| FDA | 32 |
| Fisher | 32 |
| Furin | 32 |
| M. | 32 |
| Poisson | 32 |
| Princess | 32 |
| Project | 32 |
| GGO | 32 |
| Shaanxi | 32 |
| recomendaciones | 32 |
| TCZ | 32 |
| wuhan | 32 |
| severidad | 32 |
| sanitaire | 32 |
| reducción | 32 |
| Methods | 32 |
| necesario | 32 |
| condiciones | 32 |
| West | 32 |
| Tianjin | 32 |
| criterios | 32 |
| Denmark | 31 |
| PEEP | 31 |
| Meta | 31 |
| Incubation | 31 |
| Distress | 31 |
| Discovery | 31 |
| Chunyun | 31 |
| De | 31 |
| Centers | 31 |
| Carlo | 31 |
| Bat | 31 |
| PHE | 31 |
| Assessment | 31 |
| Time | 31 |
| Si | 31 |
| sin | 31 |
| Use | 31 |
| γ | 31 |
| ya | 31 |
| utilización | 31 |
| traslado | 31 |
| _ | 31 |
| luego | 31 |
| efectos | 31 |
| disponibilidad | 31 |
| cuando | 31 |
| lesión | 31 |
| OC43 | 30 |
| 8) | 30 |
| Abbott | 30 |
| Chengdu | 30 |
| Dose | 30 |
| Ethics | 30 |
| III | 30 |
| Jiangxi | 30 |
| LIWC | 30 |
| Monte | 30 |
| November | 30 |
| SI | 30 |
| Patient | 30 |
| Qinghai | 30 |
| Saudi | 30 |
| TL | 30 |
| Trial | 30 |
| Zhongnan | 30 |
| así | 30 |
| recomendación | 30 |
| α | 30 |
| μg | 30 |
| X | 30 |
| Network | 29 |
| Sichuan | 29 |
| Romania | 29 |
| Guo | 29 |
| Hospitalized | 29 |
| CoV. | 29 |
| G2 | 29 |
| G | 29 |
| American | 29 |
| Administration | 29 |
| V5 | 29 |
| V4 | 29 |
| Inc. | 29 |
| aerosoles | 29 |
| hospitalaria | 29 |
| complicaciones | 29 |
| respuesta | 29 |
| procedimiento | 29 |
| mit | 29 |
| infecciones | 29 |
| síndrome | 29 |
| hepatitis | 29 |
| evaluar | 29 |
| estándar | 29 |
| consentimiento | 29 |
| ¼ | 29 |
| General | 28 |
| Protein | 28 |
| Log | 28 |
| Iran | 28 |
| Information | 28 |
| District | 28 |
| Escherichia | 28 |
| Epidemiological | 28 |
| Critical | 28 |
| Academy | 28 |
| Spike | 28 |
| Slovenia | 28 |
| Lopinavir | 28 |
| Th17 | 28 |
| decisión | 28 |
| Tongji | 28 |
| tanto | 28 |
| solo | 28 |
| plasma | 28 |
| disminución | 28 |
| sea | 28 |
| cada | 28 |
| aérea | 28 |
| algunos | 28 |
| Western | 28 |
| Una | 28 |
| G1-G3 | 27 |
| India | 27 |
| IS903 | 27 |
| Hospitals | 27 |
| HR | 27 |
| HLF | 27 |
| H7N9 | 27 |
| H3 | 27 |
| Guidelines | 27 |
| Bartha | 27 |
| FUNDAMENTO | 27 |
| FCS | 27 |
| Diamond | 27 |
| Department | 27 |
| Council | 27 |
| Coronavírus | 27 |
| Angiotensin | 27 |
| ALT | 27 |
| LRT | 27 |
| K61 | 27 |
| asociada | 27 |
| Lu | 27 |
| WBC | 27 |
| tet | 27 |
| sputa | 27 |
| neumonía | 27 |
| Mar | 27 |
| https://doi.org/10 | 27 |
| ensayos | 27 |
| clínicas | 27 |
| Y.N.W. | 27 |
| mid | 27 |
| Travel | 27 |
| Serbia | 27 |
| Romsdal | 27 |
| Pr | 27 |
| PT | 27 |
| PCV13 | 27 |
| NLIA | 27 |
| Møre | 27 |
| Cochrane | 26 |
| H1 | 26 |
| GAD-7 | 26 |
| Factors | 26 |
| Es | 26 |
| Corona | 26 |
| COVID‐19 | 26 |
| Children | 26 |
| Cheng | 26 |
| Pearson | 26 |
| CDCP | 26 |
| CD8 | 26 |
| PaO2 | 26 |
| Chest | 26 |
| S. | 26 |
| evitar | 26 |
| Shi | 26 |
| también | 26 |
| sus | 26 |
| revisión | 26 |
| medicamentos | 26 |
| volumen | 26 |
| disminuir | 26 |
| análisis | 26 |
| antes | 26 |
| Xiao | 26 |
| Statistical | 26 |
| NCBI | 25 |
| AP | 25 |
| Belgium | 25 |
| Effect | 25 |
| Eq | 25 |
| Evaluation | 25 |
| Guangxi | 25 |
| HSCT | 25 |
| Ill | 25 |
| Kingdom | 25 |
| Ltd. | 25 |
| Yao | 25 |
| tener | 25 |
| coronavirus | 25 |
| ct | 25 |
| general | 25 |
| i | 25 |
| información | 25 |
| médico | 25 |
| según | 25 |
| teniendo | 25 |
| trabajo | 25 |
| β | 25 |
| aumento | 25 |
| Lung | 24 |
| K | 24 |
| River | 24 |
| Patienten | 24 |
| Imperial | 24 |
| Jin | 24 |
| Acute | 24 |
| IGIV | 24 |
| Healthcare | 24 |
| HKU1 | 24 |
| Coronaviruses | 24 |
| CSF | 24 |
| < | 24 |
| Reviews | 24 |
| Provincial | 24 |
| Shandong | 24 |
| efecto | 24 |
| Viruses | 24 |
| tomar | 24 |
| servicios | 24 |
| series | 24 |
| momento | 24 |
| intensivo | 24 |
| parte | 24 |
| cordon | 24 |
| comité | 24 |
| apoyo | 24 |
| acuerdo | 24 |
| Yan | 24 |
| Xiaogan | 24 |
| F1 | 23 |
| Systematic | 23 |
| Real | 23 |
| Nanjing | 23 |
| Lin | 23 |
| H13 | 23 |
| Feng | 23 |
| Air | 23 |
| Editor | 23 |
| Delhi | 23 |
| DTW | 23 |
| DCCA | 23 |
| Chloroquine | 23 |
| Canada | 23 |
| Vietnam | 23 |
| Taxonomy | 23 |
| adversos | 23 |
| Weibull | 23 |
| renal | 23 |
| × | 23 |
| von | 23 |
| viral | 23 |
| Wenzhou | 23 |
| uno | 23 |
| través | 23 |
| veces | 23 |
| nd | 23 |
| médica | 23 |
| informado | 23 |
| importante | 23 |
| eventos | 23 |
| beneficio | 23 |
| X4 | 23 |
| Fuerte | 22 |
| Program | 22 |
| PHQ-9 | 22 |
| North | 22 |
| Migration | 22 |
| Juan | 22 |
| Heart | 22 |
| H. | 22 |
| H | 22 |
| Ritonavir | 22 |
| Fu | 22 |
| Field | 22 |
| Feb. | 22 |
| CK | 22 |
| Betacoronavirus | 22 |
| Australia | 22 |
| Associated | 22 |
| AAI | 22 |
| RECOMENDACIÓN | 22 |
| st | 22 |
| Seroprevalence | 22 |
| estrategias | 22 |
| tienen | 22 |
| significativa | 22 |
| sensibilidad | 22 |
| presencia | 22 |
| muestras | 22 |
| hospitalizados | 22 |
| está | 22 |
| Structure | 22 |
| elevación | 22 |
| crítica | 22 |
| asociado | 22 |
| aire | 22 |
| Zengdu | 22 |
| X3 | 22 |
| Wickramasinghe | 22 |
| debido | 22 |
| EM | 21 |
| PubMed | 21 |
| Plasma | 21 |
| Perboyre | 21 |
| Outcomes | 21 |
| Huanggang | 21 |
| HCID | 21 |
| Fujian | 21 |
| Chan | 21 |
| ECDC | 21 |
| Database | 21 |
| DIC | 21 |
| Cases | 21 |
| CVRP | 21 |
| CA | 21 |
| Antibody | 21 |
| V | 21 |
| Un | 21 |
| SpO2 | 21 |
| Zhong | 21 |
| muestra | 21 |
| adultos | 21 |
| tratados | 21 |
| toma | 21 |
| siguientes | 21 |
| requiere | 21 |
| objetivo | 21 |
| necesidad | 21 |
| multicentre | 21 |
| reanimación | 21 |
| medición | 21 |
| fuera | 21 |
| establecer | 21 |
| escala | 21 |
| críticamente | 21 |
| carga | 21 |
| anticuerpos | 21 |
| invasiva | 21 |
| ML | 20 |
| Geneva | 20 |
| Hu | 20 |
| Huoshenshan | 20 |
| LSTM | 20 |
| SD | 20 |
| NCP | 20 |
| Para | 20 |
| SEIRD | 20 |
| Effectiveness | 20 |
| Expert | 20 |
| Biotech | 20 |
| Drug | 20 |
| Community | 20 |
| CoV2 | 20 |
| Clet | 20 |
| Carlos | 20 |
| CVD | 20 |
| CRRT | 20 |
| COPD | 20 |
| Application | 20 |
| Teaching | 20 |
| Scientific | 20 |
| Chi | 20 |
| Washington | 20 |
| marzo | 20 |
| agudo | 20 |
| siendo | 20 |
| rutinaria | 20 |
| retrospectivo | 20 |
| residuos | 20 |
| punto | 20 |
| tasa | 20 |
| prueba | 20 |
| presenta | 20 |
| mejor | 20 |
| sedación | 20 |
| kb | 20 |
| city | 20 |
| analysis | 20 |
| gestión | 20 |
| calidad | 20 |
| ante | 20 |
| einer | 20 |
| estado | 20 |
| factores | 20 |
| frecuencia | 20 |
| Ref | 19 |
| Emerging | 19 |
| Mann | 19 |
| Latin | 19 |
| Kawasaki | 19 |
| Heilongjiang | 19 |
| H38 | 19 |
| Government | 19 |
| G1 | 19 |
| Cardiac | 19 |
| Deng | 19 |
| D. | 19 |
| Convalescent | 19 |
| Cancer | 19 |
| CPC | 19 |
| AUC | 19 |
| AQI | 19 |
| Tocilizumab | 19 |
| Studies | 19 |
| Coronaviridae | 19 |
| Whitney | 19 |
| dificultad | 19 |
| Yuan | 19 |
| rutina | 19 |
| methotrexate | 19 |
| incluyendo | 19 |
| grupos | 19 |
| evaluaron | 19 |
| enfermo | 19 |
| eine | 19 |
| evolución | 19 |
| deterioro | 19 |
| dentro | 19 |
| curso | 19 |
| contexto | 19 |
| committee | 19 |
| camas | 19 |
| azithromycin | 19 |
| asociación | 19 |
| desenlaces | 19 |
| Ji'nan | 18 |
| Liang | 18 |
| Leishenshan | 18 |
| KCDC | 18 |
| IBM | 18 |
| Int | 18 |
| Initiative | 18 |
| IS4 | 18 |
| Hull | 18 |
| Lymphopenia | 18 |
| Luminex | 18 |
| Nature | 18 |
| M-9 | 18 |
| MCL | 18 |
| MCR-1 | 18 |
| MEE | 18 |
| MMO | 18 |
| Ma | 18 |
| NGS | 18 |
| NS5A | 18 |
| Herpes | 18 |
| Norwegian | 18 |
| Novo | 18 |
| Herpesviridae | 18 |
| Enterobacteriaceae | 18 |
| Hangzhou | 18 |
| Guidance | 18 |
| PIB | 18 |
| Applied | 18 |
| Biosystems | 18 |
| CL | 18 |
| COV | 18 |
| CRE | 18 |
| CTX | 18 |
| CerTest | 18 |
| Clin | 18 |
| Consensus | 18 |
| Dear | 18 |
| Dis | 18 |
| EHV-1 | 18 |
| Earth | 18 |
| F.L. | 18 |
| FMT | 18 |
| FiO2 | 18 |
| G1-treatment | 18 |
| G3 | 18 |
| GCA_900513855.1 | 18 |
| GenBank | 18 |
| One | 18 |
| PM2 | 18 |
| PJIR | 18 |
| pMRVIM0813 | 18 |
| enfermos | 18 |
| final | 18 |
| frente | 18 |
| función | 18 |
| hallazgos | 18 |
| hospitalización | 18 |
| hydroxychloroquine | 18 |
| manifestaciones | 18 |
| mcr-8 | 18 |
| otras | 18 |
| perfusión | 18 |
| duración | 18 |
| phylogroup | 18 |
| presentaron | 18 |
| protocolo | 18 |
| protocolos | 18 |
| ptxA | 18 |
| retiro | 18 |
| significativamente | 18 |
| sistemática | 18 |
| tocilizumab | 18 |
| unidades | 18 |
| elementos | 18 |
| metalloprotein | 18 |
| disease | 18 |
| ST23 | 18 |
| cytomegalovirus | 18 |
| Poland | 18 |
| Poller | 18 |
| Progenie | 18 |
| Qiu | 18 |
| RealCycler | 18 |
| RealTime | 18 |
| Receptor | 18 |
| SHV-11 | 18 |
| SOF | 18 |
| Peng | 18 |
| Salmonella | 18 |
| Yangtze | 18 |
| Situation | 18 |
| cambios | 18 |
| adecuado | 18 |
| Zaragoza | 18 |
| cupin | 18 |
| Vero | 18 |
| Universitario | 18 |
| Sun | 18 |
| Gao | 17 |
| P<0.001 | 17 |
| OD | 17 |
| Mental | 17 |
| MCMC | 17 |
| Laboratory | 17 |
| LPV | 17 |
| Pulmonary | 17 |
| Infections | 17 |
| Infected | 17 |
| Guan | 17 |
| Cryo | 17 |
| GWR | 17 |
| Fangcang | 17 |
| English | 17 |
| David | 17 |
| Cronbach | 17 |
| Creative | 17 |
| Commons | 17 |
| COVID-2019 | 17 |
| Based | 17 |
| Adults | 17 |
| Therapy | 17 |
| Service | 17 |
| Cao | 17 |
| VTE | 17 |
| mediante | 17 |
| Xie | 17 |
| σ | 17 |
| términos | 17 |
| social | 17 |
| ≥ | 17 |
| sistema | 17 |
| requieren | 17 |
| reportaron | 17 |
| procesos | 17 |
| proceso | 17 |
| seguimiento | 17 |
| kcal | 17 |
| edad | 17 |
| humano | 17 |
| aún | 17 |
| central | 17 |
| después | 17 |
| Zheng | 17 |
| esto | 17 |
| evaluación | 17 |
| extubación | 17 |
| fase | 17 |
| NCIP | 16 |
| Huazhong | 16 |
| Index | 16 |
| Jingzhou | 16 |
| Microbiology | 16 |
| Mission | 16 |
| News | 16 |
| NO2 | 16 |
| Gyeongbuk | 16 |
| Phase | 16 |
| SARS-2 | 16 |
| Section | 16 |
| Han | 16 |
| Blood | 16 |
| Genome | 16 |
| GISAID | 16 |
| Epidemiologic | 16 |
| Environ | 16 |
| Education | 16 |
| Director | 16 |
| DBIL | 16 |
| Cohen | 16 |
| Cluster | 16 |
| CRB-65 | 16 |
| CIS | 16 |
| TCM | 16 |
| Azithromycin | 16 |
| ARB | 16 |
| Stage | 16 |
| Sarbecovirus | 16 |
| U.S. | 16 |
| implementación | 16 |
| Unit | 16 |
| ± | 16 |
| valoración | 16 |
| unidad | 16 |
| trabajadores | 16 |
| siempre | 16 |
| riesgos | 16 |
| reducir | 16 |
| prono | 16 |
| probabilidad | 16 |
| ningún | 16 |
| muy | 16 |
| intervenciones | 16 |
| pruebas | 16 |
| ensayo | 16 |
| comparado | 16 |
| enfermedades | 16 |
| Ying | 16 |
| Zhengzhou | 16 |
| adecuada | 16 |
| bronchoalveolar | 16 |
| capacidad | 16 |
| Wuchang | 16 |
| complejidad | 16 |
| contaminación | 16 |
| datos | 16 |
| daño | 16 |
| disponible | 16 |
| Party | 15 |
| MuLBSTA | 15 |
| NHC | 15 |
| NIV | 15 |
| Northern | 15 |
| OR | 15 |
| ORF1ab | 15 |
| Staff | 15 |
| Quality | 15 |
| MD | 15 |
| Statistics | 15 |
| Suizhou | 15 |
| Summary | 15 |
| VMNI | 15 |
| Markov | 15 |
| Area | 15 |
| Interventions | 15 |
| ID-19 | 15 |
| Genomic | 15 |
| Gabriel | 15 |
| Features | 15 |
| Esto | 15 |
| Environmental | 15 |
| E6 | 15 |
| Delta | 15 |
| Dec | 15 |
| Contact | 15 |
| Cell | 15 |
| CO | 15 |
| CD3 | 15 |
| Tian | 15 |
| Support | 15 |
| Yunnan | 15 |
| herramienta | 15 |
| Zeng | 15 |
| zu | 15 |
| valores | 15 |
| traqueostomía | 15 |
| tiempos | 15 |
| suficiente | 15 |
| situaciones | 15 |
| recurso | 15 |
| realizaron | 15 |
| rd | 15 |
| personas | 15 |
| monitoreo | 15 |
| mmHg | 15 |
| ij | 15 |
| rendimiento | 15 |
| hacer | 15 |
| des | 15 |
| grave | 15 |
| alteraciones | 15 |
| aplicación | 15 |
| auris | 15 |
| cardiovascular | 15 |
| cardiovasculares | 15 |
| bolsa | 15 |
| emitir | 15 |
| emodin | 15 |
| entrenamiento | 15 |
| estancia | 15 |
| expertos | 15 |
| genera | 15 |
| NLR | 14 |
| Pro | 14 |
| NP | 14 |
| Northeast | 14 |
| Norway | 14 |
| Number | 14 |
| Period | 14 |
| Population | 14 |
| Potential | 14 |
| Tool | 14 |
| RdRp | 14 |
| Res | 14 |
| Severe | 14 |
| Systems | 14 |
| TM | 14 |
| Tabla | 14 |
| Vaccine | 14 |
| Load | 14 |
| Microsoft | 14 |
| Algorithm | 14 |
| Liaoning | 14 |
| Daily | 14 |
| -3 | 14 |
| ALB | 14 |
| Xianning | 14 |
| Animal | 14 |
| Attribution | 14 |
| Br | 14 |
| DD | 14 |
| Diary | 14 |
| Level | 14 |
| Estos | 14 |
| Fan | 14 |
| Figs | 14 |
| Findings | 14 |
| Immune | 14 |
| Initial | 14 |
| LBS | 14 |
| Working | 14 |
| Shanxi | 14 |
| Yin | 14 |
| intensivista | 14 |
| ivermectin | 14 |
| leve | 14 |
| mental | 14 |
| metas | 14 |
| mostró | 14 |
| nutrición | 14 |
| posterior | 14 |
| temprana | 14 |
| todo | 14 |
| tratamientos | 14 |
| ventilatorio | 14 |
| vivo | 14 |
| werden | 14 |
| áreas | 14 |
| útil | 14 |
| Yong | 14 |
| ∼ | 14 |
| interleukin-6 | 14 |
| prevención | 14 |
| insuficiencia | 14 |
| dl | 14 |
| asociados | 14 |
| aumentar | 14 |
| inmunoglobulina | 14 |
| biomarcadores | 14 |
| cardiaca | 14 |
| condición | 14 |
| contagio | 14 |
| controles | 14 |
| caso | 14 |
| equipos | 14 |
| inicial | 14 |
| están | 14 |
| exposición | 14 |
| enfermería | 14 |
| ha | 14 |
| hospital | 14 |
| Ningbo | 13 |
| Qi | 13 |
| Safety | 13 |
| Qing | 13 |
| PSQI | 13 |
| Pathogenicity | 13 |
| PCT | 13 |
| Occupational | 13 |
| Search | 13 |
| School | 13 |
| Xue | 13 |
| Spread | 13 |
| Times | 13 |
| UEL | 13 |
| Ventilation | 13 |
| Version | 13 |
| Xi'an | 13 |
| Y. | 13 |
| Young | 13 |
| Z | 13 |
| NL63 | 13 |
| Newcastle | 13 |
| August | 13 |
| Modelling | 13 |
| Jean | 13 |
| ant | 13 |
| ADE | 13 |
| Ang | 13 |
| Army | 13 |
| BMI | 13 |
| Baltimore | 13 |
| Baricitinib | 13 |
| COVID- | 13 |
| California | 13 |
| Critically | 13 |
| Design | 13 |
| Elsevier | 13 |
| Esta | 13 |
| Finland | 13 |
| Gansu | 13 |
| ICTV | 13 |
| IES | 13 |
| IL | 13 |
| Importation | 13 |
| anakinra | 13 |
| CQ | 13 |
| aunque | 13 |
| protein | 13 |
| otro | 13 |
| paro | 13 |
| participantes | 13 |
| posibilidad | 13 |
| presentan | 13 |
| primera | 13 |
| primeras | 13 |
| profesionales | 13 |
| protectora | 13 |
| respirador | 13 |
| nos | 13 |
| rápida | 13 |
| sanitario | 13 |
| saturación | 13 |
| terapéutico | 13 |
| ti | 13 |
| tórax | 13 |
| vez | 13 |
| μmol | 13 |
| cuanto | 13 |
| novo | 13 |
| respecto | 13 |
| moderado | 13 |
| específicos | 13 |
| cánula | 13 |
| mayores | 13 |
| demostrado | 13 |
| descrito | 13 |
| directa | 13 |
| disfunción | 13 |
| escalas | 13 |
| escenarios | 13 |
| específico | 13 |
| ello | 13 |
| esté | 13 |
| existe | 13 |
| hay | 13 |
| incluidos | 13 |
| incluye | 13 |
| investigación | 13 |
| limitaciones | 13 |
| estar | 13 |
| mascarilla | 13 |
| mayo | 13 |
| Life | 12 |
| Modeling | 12 |
| P. | 12 |
| NY | 12 |
| NPIs | 12 |
| Mountain | 12 |
| Measures | 12 |
| Mobility | 12 |
| Meng | 12 |
| Media | 12 |
| Lv | 12 |
| PICU | 12 |
| PHEIC | 12 |
| W. | 12 |
| Prof. | 12 |
| S4 | 12 |
| Sci | 12 |
| Sweden | 12 |
| Síndrome | 12 |
| TB | 12 |
| TGMH | 12 |
| Tao | 12 |
| Tencent | 12 |
| WS | 12 |
| Wen | 12 |
| Liao | 12 |
| Liberation | 12 |
| Berlin | 12 |
| Language | 12 |
| Concern | 12 |
| A. | 12 |
| African | 12 |
| Al | 12 |
| Anxiety | 12 |
| BD | 12 |
| X1 | 12 |
| CCMU | 12 |
| Cardiovascular | 12 |
| Chicago | 12 |
| CoVZXC21 | 12 |
| Colombia | 12 |
| Communist | 12 |
| DPP4 | 12 |
| Kang | 12 |
| Diagnostics | 12 |
| DosePM2.5 | 12 |
| Epidemia | 12 |
| Extended | 12 |
| Ezhou | 12 |
| Fast | 12 |
| G. | 12 |
| HR1 | 12 |
| Hopkins | 12 |
| I(2 | 12 |
| IH | 12 |
| Identification | 12 |
| Wenliang | 12 |
| Spearman | 12 |
| Xi | 12 |
| pulmonares | 12 |
| marcadores | 12 |
| médicos | 12 |
| múltiples | 12 |
| negativa | 12 |
| negativos | 12 |
| ni | 12 |
| orotraqueal | 12 |
| oseltamivir | 12 |
| población | 12 |
| primeros | 12 |
| procedimientos | 12 |
| progresión | 12 |
| qué | 12 |
| j.jinf.2020.02.019 | 12 |
| relación | 12 |
| resolución | 12 |
| sich | 12 |
| signos | 12 |
| solución | 12 |
| supervivencia | 12 |
| tasas | 12 |
| tracto | 12 |
| troponina | 12 |
| técnicas | 12 |
| | 12 |
| Xiang | 12 |
| líquidos | 12 |
| realiza | 12 |
| institucional | 12 |
| cohorte | 12 |
| Xinmiao | 12 |
| iniciar | 12 |
| Ye | 12 |
| Yun | 12 |
| Zika | 12 |
| antiepidemic | 12 |
| años | 12 |
| bei | 12 |
| beneficios | 12 |
| capacitación | 12 |
| catéter | 12 |
| choque | 12 |
| basado | 12 |
| col | 12 |
| fecha | 12 |
| inflamación | 12 |
| https://doi.org/10.1101/2020.03.04.20026005 | 12 |
| hace | 12 |
| gravedad | 12 |
| forma | 12 |
| fármacos | 12 |
| documento | 12 |
| diferencias | 12 |
| detección | 12 |
| definir | 12 |
| combinación | 12 |
| Practice | 11 |
| NTD | 11 |
| Positive | 11 |
| PTSS | 11 |
| Origin | 11 |
| Open | 11 |
| Normal | 11 |
| Lockdown | 11 |
| NEWS-2 | 11 |
| Min | 11 |
| Mid | 11 |
| Lymr | 11 |
| Kaplan | 11 |
| Leung | 11 |
| Preliminary | 11 |
| Prediction | 11 |
| Steele | 11 |
| Prism | 11 |
| Shincheonji | 11 |
| Jinyintan | 11 |
| TX | 11 |
| T. | 11 |
| Strogatz | 11 |
| Springer | 11 |
| Shuang | 11 |
| Services | 11 |
| Python | 11 |
| Sepsis | 11 |
| Score | 11 |
| Resource | 11 |
| Relative | 11 |
| Region | 11 |
| Qian | 11 |
| Johns | 11 |
| Bio | 11 |
| Italia | 11 |
| Church | 11 |
| FLRPHE | 11 |
| Este | 11 |
| Environment | 11 |
| Dynamic | 11 |
| Comprehensive | 11 |
| CoV-1 | 11 |
| CNS | 11 |
| Inspection | 11 |
| British | 11 |
| Bian | 11 |
| Arbidol | 11 |
| Albert | 11 |
| ACE | 11 |
| V3 | 11 |
| Fifth | 11 |
| GMT | 11 |
| Gong | 11 |
| Governance | 11 |
| Grad | 11 |
| Guillain | 11 |
| Guizhou | 11 |
| HBPM | 11 |
| HUST | 11 |
| Hainan | 11 |
| Host | 11 |
| Hui | 11 |
| ID | 11 |
| IL-10 | 11 |
| ISI | 11 |
| Illumina | 11 |
| Inhibitors | 11 |
| Thermo | 11 |
| -8 | 11 |
| Watts | 11 |
| papel | 11 |
| prona | 11 |
| predecir | 11 |
| posible | 11 |
| pesar | 11 |
| permite | 11 |
| patologías | 11 |
| nomogram | 11 |
| quienes | 11 |
| multicéntrico | 11 |
| ml | 11 |
| miocárdica | 11 |
| mejora | 11 |
| manos | 11 |
| línea | 11 |
| práctica | 11 |
| refractaria | 11 |
| identificar | 11 |
| tenían | 11 |
| X2 | 11 |
| ventilador | 11 |
| técnica | 11 |
| tuvieron | 11 |
| tres | 11 |
| transfusión | 11 |
| temprano | 11 |
| relacionadas | 11 |
| t. | 11 |
| sofosbuvir | 11 |
| sobrevida | 11 |
| será | 11 |
| segura | 11 |
| respiración | 11 |
| lograr | 11 |
| puntos | 11 |
| https://doi.org/10.1101/2020.03.31.20049387 | 11 |
| altas | 11 |
| cardiaco | 11 |
| bioética | 11 |
| author(s | 11 |
| aumenta | 11 |
| arritmias | 11 |
| alteración | 11 |
| admisión | 11 |
| citocinas | 11 |
| adicional | 11 |
| además | 11 |
| acceso | 11 |
| abril | 11 |
| Zhoushan | 11 |
| hidroxicloroquina | 11 |
| centro | 11 |
| anticoagulación | 11 |
| coronaviruses | 11 |
| egreso | 11 |
| health | 11 |
| fiebre | 11 |
| esteroides | 11 |
| específica | 11 |
| eliminación | 11 |
| elevados | 11 |
| hemodinámica | 11 |
| east | 11 |
| dispositivos | 11 |
| disponibles | 11 |
| disnea | 11 |
| demostró | 11 |
| deberá | 11 |
| LDA | 10 |
| Mongolia | 10 |
| Mini | 10 |
| Meier | 10 |
| MAbs | 10 |
| Long | 10 |
| Legionella | 10 |
| Labour | 10 |
| Jiangxia | 10 |
| Kim | 10 |
| Jun | 10 |
| Mycobacterium | 10 |
| Jianghan | 10 |
| Interim | 10 |
| Imai | 10 |
| Imaging | 10 |
| Mr. | 10 |
| Traditional | 10 |
| Ningxia | 10 |
| PAR | 10 |
| Hilden | 10 |
| Tohoku | 10 |
| Th | 10 |
| Statement | 10 |
| Song | 10 |
| Shen | 10 |
| SEMCR | 10 |
| SCLIWC | 10 |
| Recommendations | 10 |
| RP | 10 |
| QIAamp | 10 |
| Provinces | 10 |
| Problem | 10 |
| Pan | 10 |
| 10 | |
| IFR | 10 |
| A1 | 10 |
| HCoV-229E | 10 |
| Con | 10 |
| Clínico | 10 |
| Chain | 10 |
| CRISPR | 10 |
| COVID19 | 10 |
| CAM | 10 |
| Barr | 10 |
| Asymptomatic | 10 |
| Anti | 10 |
| Age | 10 |
| Abstract | 10 |
| AZ | 10 |
| APEC | 10 |
| ACEI | 10 |
| WH | 10 |
| 2D | 10 |
| Computing | 10 |
| Crisis | 10 |
| Gram | 10 |
| Cross | 10 |
| Gene | 10 |
| GI | 10 |
| Finalmente | 10 |
| Failure | 10 |
| FGMH | 10 |
| Epstein | 10 |
| Enterobacter | 10 |
| Eliseo | 10 |
| Efficacy | 10 |
| ESR | 10 |
| EBV | 10 |
| Dong | 10 |
| DFE | 10 |
| DALY | 10 |
| Culture | 10 |
| UI | 10 |
| Action | 10 |
| Walsh | 10 |
| monitoria | 10 |
| posibles | 10 |
| podrían | 10 |
| peso | 10 |
| parámetros | 10 |
| paliativos | 10 |
| necesarios | 10 |
| national | 10 |
| modelos | 10 |
| hubo | 10 |
| marco | 10 |
| mRNA | 10 |
| lugar | 10 |
| intervención | 10 |
| intensidad | 10 |
| incluir | 10 |
| impacto | 10 |
| positivity | 10 |
| posteriores | 10 |
| primer | 10 |
| propone | 10 |
| Waste | 10 |
| Δ | 10 |
| óptimo | 10 |
| éticos | 10 |
| área | 10 |
| van | 10 |
| todas | 10 |
| sulfamethoxazole | 10 |
| situación | 10 |
| sistemas | 10 |
| secuelas | 10 |
| rt | 10 |
| reportado | 10 |
| quien | 10 |
| puntaje | 10 |
| identificación | 10 |
| recuperación | 10 |
| hospitales | 10 |
| comparación | 10 |
| características | 10 |
| cadáver | 10 |
| asoció | 10 |
| aparición | 10 |
| alveolar | 10 |
| ajustar | 10 |
| aislamiento | 10 |
| Z. | 10 |
| Yi | 10 |
| Xin | 10 |
| Wilcoxon | 10 |
| 10 | |
| Wavelet | 10 |
| hacia | 10 |
| Wave | 10 |
| chemoprophylaxis | 10 |
| adecuación | 10 |
| componentes | 10 |
| determinar | 10 |
| guías | 10 |
| generales | 10 |
| confirmado | 10 |
| experiencia | 10 |
| encontraron | 10 |
| ellos | 10 |
| diferencia | 10 |
| efectividad | 10 |
| desinfectante | 10 |
| das | 10 |
| confirmados | 10 |
| células | 10 |
| cuadro | 10 |
| continuo | 10 |
| considera | 10 |
| Kebbi | 9 |
| MALDI | 9 |
| MCR | 9 |
| MB | 9 |
| Loughborough | 9 |
| Luzatti | 9 |
| Jing | 9 |
| Key | 9 |
| Leismania | 9 |
| MGIT | 9 |
| MCR-9 | 9 |
| Material | 9 |
| MIC | 9 |
| MN908947.3 | 9 |
| Maidenhead | 9 |
| Manchester | 9 |
| Maritati | 9 |
| Maryland | 9 |
| Mechanism | 9 |
| Medicina | 9 |
| Jia | 9 |
| Mengmeng | 9 |
| Metagenomic | 9 |
| Jilin | 9 |
| Hill | 9 |
| Jensen | 9 |
| Hua | 9 |
| Mycobacteria | 9 |
| HRCT | 9 |
| Haberling | 9 |
| Hafnia | 9 |
| Harbin | 9 |
| Hb | 9 |
| Hercules | 9 |
| HiSeq | 9 |
| Holshue | 9 |
| Hortega | 9 |
| IAME | 9 |
| Jandrić | 9 |
| IC90 | 9 |
| INSERM | 9 |
| IPD | 9 |
| IS30 | 9 |
| Indicator | 9 |
| Irrua | 9 |
| Isolation | 9 |
| Italian | 9 |
| JCYJ20170303155012371 | 9 |
| JR18/0 | 9 |
| Microbiol | 9 |
| Rad | 9 |
| Médecins | 9 |
| Randomized | 9 |
| Psoriasis | 9 |
| PwMS | 9 |
| QIA | 9 |
| QT | 9 |
| RGNOSIS | 9 |
| RIT | 9 |
| RITM | 9 |
| RVP | 9 |
| HCU- | 9 |
| Radiology | 9 |
| Reactive | 9 |
| Procalcitonin | 9 |
| Renmin | 9 |
| Reporting | 9 |
| Researchers | 9 |
| Resistance | 9 |
| Rhinolophus | 9 |
| Rodés | 9 |
| Routing | 9 |
| Río | 9 |
| SARI | 9 |
| SDS | 9 |
| Promotion | 9 |
| Preparedness | 9 |
| N. | 9 |
| PBRT | 9 |
| NDM | 9 |
| NS5B | 9 |
| Neutrophil | 9 |
| OMB | 9 |
| OXA-10 | 9 |
| Ondo | 9 |
| Oxford | 9 |
| Oxoid | 9 |
| PAFI | 9 |
| PAH | 9 |
| PN:52906 | 9 |
| Polymyxin | 9 |
| PP | 9 |
| Palermo | 9 |
| Paolo | 9 |
| Pediatric | 9 |
| Plan | 9 |
| Plasmid | 9 |
| Platelia | 9 |
| PneumoVir | 9 |
| Pneumocysis | 9 |
| Politécnico | 9 |
| HFNC | 9 |
| EHV8 | 9 |
| H5N6 | 9 |
| Brunet | 9 |
| Background | 9 |
| Barré | 9 |
| Bayesian | 9 |
| Becton | 9 |
| Belfast | 9 |
| Biomerieux | 9 |
| Bordetella | 9 |
| Boyan | 9 |
| Brain | 9 |
| Brazil | 9 |
| CJAD | 9 |
| B.L.Z. | 9 |
| CLART | 9 |
| CM18/00221 | 9 |
| CMY-16 | 9 |
| CXR | 9 |
| Cai | 9 |
| Career | 9 |
| Castle | 9 |
| Catholics | 9 |
| Chang | 9 |
| Chowdhury | 9 |
| BCYE | 9 |
| Authority | 9 |
| Guideline | 9 |
| Ag | 9 |
| SOD | 9 |
| 0ed3c6a5559cd73307184f51fc53ccc76da559bc | 9 |
| 1/3200 | 9 |
| 3D | 9 |
| 3a | 9 |
| 3rd | 9 |
| 500/125 | 9 |
| A(H7N4 | 9 |
| ABI | 9 |
| AIDS | 9 |
| Alliance | 9 |
| Author | 9 |
| Alphaherpesvirinae | 9 |
| Amin | 9 |
| Amirthalingam | 9 |
| Amphotericin | 9 |
| Antibiotic | 9 |
| Antimicrobial | 9 |
| Approach | 9 |
| Aspergillus | 9 |
| Aujeszky | 9 |
| Austin | 9 |
| Chun | 9 |
| Colonization | 9 |
| Comparative | 9 |
| G4 | 9 |
| F. | 9 |
| Fatigue | 9 |
| Fe | 9 |
| Fellowship | 9 |
| Filmarray | 9 |
| Fischer | 9 |
| Five | 9 |
| Flu | 9 |
| Frontières | 9 |
| G.P.Z. | 9 |
| GCA_900501685.1 | 9 |
| Contigs | 9 |
| GENE | 9 |
| GIS | 9 |
| GLE | 9 |
| GRZ | 9 |
| Genomica | 9 |
| Giaccone | 9 |
| Giménez | 9 |
| Grocott | 9 |
| Growth | 9 |
| Guided | 9 |
| Excellent | 9 |
| Event | 9 |
| Estela | 9 |
| Equine | 9 |
| Coproduction | 9 |
| Corporation | 9 |
| Coslada | 9 |
| Cytospin | 9 |
| DAAs | 9 |
| Definition | 9 |
| Delphi | 9 |
| Diagnostic | 9 |
| Dickinson | 9 |
| Drigalski | 9 |
| ECIL | 9 |
| EHV1-EHV9 | 9 |
| EHV5 | 9 |
| EHVs | 9 |
| ELB | 9 |
| EU | 9 |
| EZ-1 | 9 |
| Economic | 9 |
| Edo | 9 |
| Entry | 9 |
| Enzyme | 9 |
| SEAIR | 9 |
| MIU | 9 |
| SZSM201512030 | 9 |
| mejorar | 9 |
| les | 9 |
| liberación | 9 |
| log | 9 |
| lymphocytopenia | 9 |
| mcr-1 | 9 |
| mcr-1.1 | 9 |
| mcr-3 | 9 |
| mcr-7.1 | 9 |
| medicina | 9 |
| medida | 9 |
| microcopy | 9 |
| lactato | 9 |
| modelo | 9 |
| monitorización | 9 |
| moral | 9 |
| mostraron | 9 |
| nacional | 9 |
| nervioso | 9 |
| ng | 9 |
| observacional | 9 |
| ofrecer | 9 |
| oxytoca | 9 |
| ledipasvir | 9 |
| laborato | 9 |
| pCTXM9_020038 | 9 |
| huésped | 9 |
| gasto | 9 |
| geno2pheno | 9 |
| global | 9 |
| guyanensis | 9 |
| herpesviruses | 9 |
| histopathological | 9 |
| historia | 9 |
| hormaechei | 9 |
| http://www.progenie-molecular.com/PJIR-U-IN.pdf | 9 |
| http://www.stats.gov.cn/tjsj/zxfb/ | 9 |
| hygromycin | 9 |
| key | 9 |
| immunoprophylaxis | 9 |
| implementar | 9 |
| incidencia | 9 |
| incluso | 9 |
| incremento | 9 |
| infantum | 9 |
| infectados | 9 |
| inferior | 9 |
| iniciales | 9 |
| j.jinf.2020.01.019 | 9 |
| p.o | 9 |
| pME-1a | 9 |
| formación | 9 |
| ±60 | 9 |
| tomografía | 9 |
| total | 9 |
| trimethoprim | 9 |
| trombosis | 9 |
| uploads/2019/02 | 9 |
| ward | 9 |
| wpontent | 9 |
| www.geno2pheno.org | 9 |
| www.gov.uk/government/publications/wuhan-novelcoronavirus-infection-prevention-and-control/wuhan-novel-coronavirus-wncov-infection-prevention-and-control-guidance | 9 |
| ±3 | 9 |
| ±70 | 9 |
| terapéutica | 9 |
| ésta | 9 |
| índices | 9 |
| último | 9 |
| λ(t | 9 |
| −2 | 9 |
| −92 | 9 |
| ∼28 | 9 |
| ∼8.7 | 9 |
| ≥400 | 9 |
| Sabouraud | 9 |
| tet(X | 9 |
| tenía | 9 |
| panamensis | 9 |
| publicación | 9 |
| phenicols | 9 |
| plan | 9 |
| pneumococci | 9 |
| pneumocystis | 9 |
| pneumoniae | 9 |
| positivos | 9 |
| predictores | 9 |
| presentación | 9 |
| previamente | 9 |
| primero | 9 |
| qSOFA | 9 |
| temperatura | 9 |
| quasipneumoniae | 9 |
| razonable | 9 |
| resistencia | 9 |
| ries | 9 |
| sintomatología | 9 |
| sp1.pdf | 9 |
| sugieren | 9 |
| sul2 | 9 |
| t.d.s | 9 |
| telesalud | 9 |
| galactomannan | 9 |
| paralvei | 9 |
| fold | 9 |
| Vehicle | 9 |
| Thrombocytopenia | 9 |
| Transport | 9 |
| Tube)/Lowenstein | 9 |
| Tyne | 9 |
| Typhimurium | 9 |
| UMR-1137 | 9 |
| Université | 9 |
| VEL | 9 |
| VIASURE | 9 |
| Varicellovirus | 9 |
| WGS | 9 |
| TEM-1 | 9 |
| Welders | 9 |
| Wellcome | 9 |
| Wh | 9 |
| Wong | 9 |
| XF | 9 |
| Xiangyang | 9 |
| Xinjiang | 9 |
| Xiong | 9 |
| Y.F.H. | 9 |
| Yichang | 9 |
| TOF | 9 |
| Symphony | 9 |
| ZC45 | 9 |
| SoC | 9 |
| San | 9 |
| fenotipos | 9 |
| Sanatorium | 9 |
| Sanger | 9 |
| Sanming | 9 |
| Sans | 9 |
| Scale | 9 |
| Semiquantitative | 9 |
| Serotype | 9 |
| Shaw | 9 |
| Sophia | 9 |
| Survey | 9 |
| Sothern | 9 |
| Sport | 9 |
| Sputa | 9 |
| Sputasol | 9 |
| Stress | 9 |
| Su | 9 |
| Subclinical | 9 |
| Suidae | 9 |
| SuperPolymyxin | 9 |
| Superpolymyxin | 9 |
| Z/18 | 9 |
| TMP/800 | 9 |
| Zamfara | 9 |
| diffuse | 9 |
| content/10.1101/2020.02.12.20022327v1 | 9 |
| continua | 9 |
| crystalloid | 9 |
| cuidado | 9 |
| d2 | 9 |
| dados | 9 |
| definida | 9 |
| den | 9 |
| department | 9 |
| dexametasona | 9 |
| difícil | 9 |
| compararon | 9 |
| dímero | 9 |
| eHealth | 9 |
| eficacia | 9 |
| endophthalmitis | 9 |
| enterobacter | 9 |
| epidemia | 9 |
| especificidad | 9 |
| espontánea | 9 |
| estén | 9 |
| familia | 9 |
| consenso | 9 |
| desinfección | 9 |
| amazonensis | 9 |
| assembly | 9 |
| comorbilidades | 9 |
| Zuqin | 9 |
| ab | 9 |
| acerca | 9 |
| administración | 9 |
| alerta | 9 |
| aph(4)-Ia | 9 |
| aquellos | 9 |
| asistencial | 9 |
| ✩ | 9 |
| Zhongyan | 9 |
| ausencia | 9 |
| blaVIM-4-and | 9 |
| bloqueo | 9 |
| calcofluor | 9 |
| cambio | 9 |
| carbapenem | 9 |
| chronic | 9 |
| citoquinas | 9 |
| claro | 9 |
| Zhongyu | 9 |
| Protocol | 8 |
| Personal | 8 |
| Position | 8 |
| Post | 8 |
| Protection | 8 |
| Lee | 8 |
| Regulations | 8 |
| Ren | 8 |
| Richard | 8 |
| Pangolin | 8 |
| Régis | 8 |
| Pattern | 8 |
| Ling | 8 |
| Pacific | 8 |
| PaO | 8 |
| PRISMA | 8 |
| ORF8 | 8 |
| Mortality | 8 |
| Mar. | 8 |
| Manual | 8 |
| Manejo | 8 |
| MWC | 8 |
| MEDLINE | 8 |
| Lian | 8 |
| SR | 8 |
| SIS | 8 |
| Yue | 8 |
| Scopus | 8 |
| Tibet | 8 |
| LZ | 8 |
| association | 8 |
| antimaláricos | 8 |
| azitromicina | 8 |
| YX | 8 |
| Workers | 8 |
| WAIC | 8 |
| Virology | 8 |
| VOC | 8 |
| Total | 8 |
| Tong | 8 |
| Theory | 8 |
| Second | 8 |
| Testing | 8 |
| Test | 8 |
| Task | 8 |
| Tan | 8 |
| Tab | 8 |
| Switzerland | 8 |
| Surveillance | 8 |
| Surto | 8 |
| Subgroup | 8 |
| Stability | 8 |
| Semiformal | 8 |
| Lai | 8 |
| Airborne | 8 |
| LAMP | 8 |
| Bank | 8 |
| Ct | 8 |
| Corticosteroid | 8 |
| Como | 8 |
| Coherence | 8 |
| Co. | 8 |
| Cities | 8 |
| COVID-19-related | 8 |
| Bureau | 8 |
| Breakthrough | 8 |
| Blue | 8 |
| Biotechnology | 8 |
| BMJ | 8 |
| Depression | 8 |
| BCG | 8 |
| Authorization | 8 |
| Armonk | 8 |
| ArcGIS | 8 |
| Alphacoronavirus | 8 |
| Airport | 8 |
| Affairs | 8 |
| Adult | 8 |
| ACV | 8 |
| ACO | 8 |
| base | 8 |
| Da | 8 |
| Disaster | 8 |
| Jingmen | 8 |
| Handbook | 8 |
| Jie | 8 |
| JL | 8 |
| JAMA | 8 |
| Investigating | 8 |
| Inner | 8 |
| Inference | 8 |
| Individual | 8 |
| IL-1 | 8 |
| ICUs | 8 |
| Huangshi | 8 |
| Headquarters | 8 |
| 8 | |
| Dr | 8 |
| Gautam | 8 |
| GZ02 | 8 |
| GS-5734 | 8 |
| GD | 8 |
| François | 8 |
| Force | 8 |
| FFP2 | 8 |
| Excel | 8 |
| Evolution | 8 |
| Engineering | 8 |
| Embase | 8 |
| bajos | 8 |
| incluyeron | 8 |
| bioseguridad | 8 |
| primario | 8 |
| replicación | 8 |
| reciente | 8 |
| realizarse | 8 |
| quirúrgica | 8 |
| puedan | 8 |
| publicado | 8 |
| publicaciones | 8 |
| proteína | 8 |
| pronación | 8 |
| profunda | 8 |
| procalcitonina | 8 |
| prevenir | 8 |
| rápidamente | 8 |
| preoxigenación | 8 |
| positivo | 8 |
| patología | 8 |
| optimizar | 8 |
| obtener | 8 |
| objetivos | 8 |
| nítrico | 8 |
| neurológicas | 8 |
| negativas | 8 |
| necesaria | 8 |
| mínimo | 8 |
| respiradores | 8 |
| s(+∞ | 8 |
| muerte | 8 |
| variabilidad | 8 |
| broncoscopia | 8 |
| ε | 8 |
| óxido | 8 |
| ética | 8 |
| | | 8 |
| xxx | 8 |
| wird | 8 |
| vital | 8 |
| virales | 8 |
| ventilados | 8 |
| vasculares | 8 |
| utilizados | 8 |
| sangre | 8 |
| transmisión | 8 |
| tormenta | 8 |
| tolerancia | 8 |
| sólo | 8 |
| superior | 8 |
| sobrevivientes | 8 |
| sobrecarga | 8 |
| siguiendo | 8 |
| significativo | 8 |
| serie | 8 |
| sean | 8 |
| muestran | 8 |
| segunda | 8 |
| modalidades | 8 |
| disease-2019 | 8 |
| evitando | 8 |
| estrés | 8 |
| estas | 8 |
| específicas | 8 |
| especiales | 8 |
| espacio | 8 |
| enero | 8 |
| encefalitis | 8 |
| efectiva | 8 |
| dolor | 8 |
| disposición | 8 |
| desarrollo | 8 |
| falta | 8 |
| derechos | 8 |
| demanda | 8 |
| dar | 8 |
| correlación | 8 |
| controlado | 8 |
| contar | 8 |
| colaboradores | 8 |
| cerebro | 8 |
| cerebral | 8 |
| middle | 8 |
| capilar | 8 |
| factor | 8 |
| describieron | 8 |
| frecuente | 8 |
| institucionales | 8 |
| medio | 8 |
| medicamento | 8 |
| frecuentes | 8 |
| mecanismos | 8 |
| limpieza | 8 |
| le | 8 |
| laboratorio | 8 |
| isquémico | 8 |
| intravenosa | 8 |
| interferón | 8 |
| intensivistas | 8 |
| kw | 8 |
| hemodinámico | 8 |
| ingresados | 8 |
| inflamatorios | 8 |
| indirecta | 8 |
| igual | 8 |
| hyperimmune | 8 |
| garantizar | 8 |
| https://doi.org/10.1101/2020.03.03.20030353 | 8 |
| https://doi.org/10.1101/2020.01.27.20018986 | 8 |
| group | 8 |
| grado | 8 |
| Publisher | 7 |
| Rev | 7 |
| Prof | 7 |
| Pittsburgh | 7 |
| Pulmonar | 7 |
| PRC | 7 |
| Rothe | 7 |
| Respir | 7 |
| Qianxi | 7 |
| Que | 7 |
| RTV | 7 |
| Responses | 7 |
| Retrospective | 7 |
| PDB | 7 |
| POCUS | 7 |
| Nanshan | 7 |
| P | 7 |
| Organ | 7 |
| Observational | 7 |
| OS | 7 |
| ORF1a | 7 |
| Nutrition | 7 |
| Note | 7 |
| Nishiura | 7 |
| Nipah | 7 |
| NT | 7 |
| NPI | 7 |
| NK | 7 |
| Russia | 7 |
| Mobile | 7 |
| Rt | 7 |
| anosmia | 7 |
| S5 | 7 |
| YW | 7 |
| Mechanical | 7 |
| ataque | 7 |
| aspectos | 7 |
| artículos | 7 |
| antivirales | 7 |
| anterior | 7 |
| altos | 7 |
| alternativa | 7 |
| agua | 7 |
| ageusia | 7 |
| agentes | 7 |
| adecuadamente | 7 |
| actividades | 7 |
| X. | 7 |
| SEIQR | 7 |
| Wikipedia | 7 |
| W | 7 |
| Unknown | 7 |
| Ultrasound | 7 |
| Transportation | 7 |
| Theorem | 7 |
| Tables | 7 |
| TH | 7 |
| Stroke | 7 |
| Strategies | 7 |
| Shu | 7 |
| Sheng | 7 |
| Seoul | 7 |
| Mechanisms | 7 |
| Bin | 7 |
| Matrix | 7 |
| Capital | 7 |
| ECG | 7 |
| Dímero | 7 |
| Dysregulation | 7 |
| Disease-2019 | 7 |